Literature DB >> 30519923

Apocrine papillary lesion: comparison of pathological findings from 22 years previously and the present.

Yuki Nomoto1, Heiji Yoshinaka2, Yasuyo Ohi3, Naoki Hayashi2, Ayako Nagata2, Kazunobu Sueyoshi4, Yuka Eguchi5, Yoshiaki Shinden5, Yuko Kijima5, Shoji Natsugoe5.   

Abstract

Apocrine papillary lesion (APL) is difficult to diagnose as benign or malignant. We experienced an APL remaining in the body for 22 years. We present a case of a 71-year-old woman who had undergone excisional biopsy 22 years previously at the first hospital that she visited. 1 year previously, she had undergone fine-needle aspiration cytology at a second hospital, and the lesion was diagnosed as potentially malignant. She underwent core-needle biopsy at a third hospital, but whether the lesion was benign or malignant could not be definitively diagnosed. We performed right mastectomy and sentinel lymph-node biopsy, because her tumor was suspected to be malignant based on imaging means, and malignancy could not be ruled out on either biopsy or cytology. The histopathological diagnosis was tiny foci of apocrine proliferative lesion with massive hemorrhagic necrosis and no tumor metastasis in two sentinel lymph nodes. Retrospectively, we compared all of the patient's previous specimens with the present ones, and applied the recent pathological diagnostic criteria. Although the biopsy specimen excised 22 years ago suggested an encapsulated apocrine papillary carcinoma or a papilloma with apocrine ductal carcinoma in situ, neither infiltration nor metastasis has occurred. Furthermore, neither the pathological findings nor the clinical behavior has changed over time.

Entities:  

Keywords:  Apocrine papillary lesion; Encapsulated apocrine papillary carcinoma; Papilloma with DCIS

Mesh:

Year:  2018        PMID: 30519923     DOI: 10.1007/s12282-018-00936-1

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  1 in total

1.  Multiplex PCR analysis of apocrine lesions shows frequent PI3K-AKT pathway mutations in both benign and malignant apocrine breast tumors.

Authors:  Naoki Kanomata; Rin Yamaguchi; Junichi Kurebayashi; Takuya Moriya
Journal:  Med Mol Morphol       Date:  2019-05-28       Impact factor: 2.309

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.